Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies

Antonella Padella(University of Bologna), Giorgia Simonetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Andrea Ghelli Luserna di Rorà(Fondazione Pisa), Martina Ghetti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Giovanni Marconi(University of Bologna), Giovanni Martinelli(University of Bologna)
Journal of Hematology & Oncology
January 22, 2022
10.1186/s13045-022-01228-0
Cited by 103

Related Papers

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with &gt;30% blasts
|Blood|2015|1.2k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
|The Lancet Oncology|2017|493
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
|The Lancet Oncology|2019|486